News

Every Patient, Every Time

NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.

New biologic on the horizon

Izana Bioscience, a new UK based pharmaceutical company, is running a phase 2 clinical trial for 42 patients across 10 centres in the UK for its new drug,  Namilumab.

Should you get a flu jab this winter?

Flu can be more severe in certain people, including anyone aged 65 and over and people with weakened immune systems. This would include people on biologic therapies like anti TNF or anti IL 17A, on regular steroids or taking DMARDs such as methotrexate